Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Abbott Genentech |
---|---|
Information provided by: | Abbott |
ClinicalTrials.gov Identifier: | NCT00517790 |
Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Condition | Intervention | Phase |
---|---|---|
Non-Small Cell Lung Cancer (NSCLC) |
Drug: ABT-869 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study |
Official Title: | An Open-Label, Randomized, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
Enrollment: | 139 |
Study Start Date: | August 2007 |
Estimated Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
0.25 mg/kg: Experimental
High dose
|
Drug: ABT-869
0.25 mg/kg or 0.10 mg/kg
|
0.10 mg/kg: Experimental
Low Dose
|
Drug: ABT-869
0.25 mg/kg or 0.10 mg/kg
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Justin Ricker, MD | Abbott |
Responsible Party: | Abbott ( Rod Humerickhouse, MD, Global Project Head ) |
Study ID Numbers: | M06-880 |
Study First Received: | August 16, 2007 |
Last Updated: | January 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00517790 |
Health Authority: | United States: Food and Drug Administration; Singapore: Health Sciences Authority |
Thoracic Neoplasms Non-small cell lung cancer Respiratory Tract Diseases Lung Neoplasms |
Lung Diseases Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Respiratory Tract Neoplasms Neoplasms Neoplasms by Site Neoplasms by Histologic Type |